Original Article
Arturo Chayet, MD; Harkaran S. Bains
- Journal of Refractive Surgery
- February 2012 - Volume 28 · Issue 2: 112-119
-
DOI: 10.3928/1081597X-20111219-01
Abstract
PURPOSE:
To compare the postoperative outcomes of aspheric or prolate LASIK for myopia and myopic astigmatism.
METHODS:
In this double-blind, bilateral, randomized trial, 40 patients (80 eyes) with −0.75 to −7.00 diopters (D) of manifest refraction spherical equivalent (MRSE) underwent optimized aspheric treatment zone ablation (OATz group) in 1 eye and optimized prolate ablation (OPA group) in the fellow eye. Six-month postoperative outcomes were compared for MRSE and visual acuity, contrast sensitivity, patient satisfaction, ocular higher order aberrations (HOAs), and spherical aberration. The Wilcoxon signed rank test, Mann-Whitney U test, and paired t test were used for testing differences between groups. P<.05 was statistically significant. Main outcome measures included HOAs, spherical aberration, visual and refractive outcomes, and contrast sensitivity.
RESULTS:
Postoperatively, 36 patients (72 eyes) were evaluated. The MRSE was −0.07±0.23 D for the OPA group and +0.02±0.24 D for the OATz group (P>.05). Two (5%) eyes in the OPA group and 1 (3%) eye in the OATz group (P=.114) lost 1 line of corrected distance visual acuity. Postoperative visual acuity was not statistically different between groups (P>.05). Statistically lower change was noted in spherical aberration (0.011 μm) in the OPA group versus the OATz group (0.099 μm) (P<.001). Statistically higher induction of coma was noted in the OPA group (P=.035). No statistically significant differences were noted in photopic, mesopic, or glare contrast sensitivity and patient satisfaction between groups (P>.05, for all comparisons).
CONCLUSIONS:
The refractive and visual outcomes of OPA and OATz were equivalent. However, the postoperative optical quality of OPA-treated eyes was better.
AUTHORS
From CODET Vision Institute, Tijuana, Mexico (Chayet); and Edmonton, Canada (Bains).
Both authors are members of the NIDEK Co Ltd Medical Advisory Board.
The authors have no financial or proprietary interests in the materials presented herein.
Correspondence: Harkaran S. Bains, 17927-80 Ave, Edmonton, AB, Canada T5T 0S6. E-mail: hsbains@ymail.com
Received: November 30, 2010
Accepted: November 01, 2011
Posted Online: December 29, 2011
doi: 10.3928/1081597X-20111219-01